EU approves Acadia's trofinetide for Rett syndrome treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. NVDA
2. PSKY
3. META
4. LGND
5. SPY
6. MONC:IM
7. PTON
8. NYXH
9. LXEO
10. MONRY

Go back to EU approves Acadia's trofinetide for Rett syndrome treatment
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) Delayed: 26.80 +0.41 (1.55%)
Previous Close $26.39    52 Week High $42.49 
Open $26.65    52 Week Low $16.64 
Day High $26.84    P/E N/A 
Day Low $26.40    EPS $-0.42 
Volume 117,564